Superficial basal cell carcinoma treated with 70% trichloroacetic acid applied topically: a case study

Anca Chiriac1–3
Piotr Brzezinski4
Cosmin Moldovan5
Cristian Podoleanu6
Marius Florin Coros7
Simona Stolnicu8

1Department of Dermatology, Nicolina Medical Center, Iasi, 2Department of Dermatology, Apollonia University, Iasi, 3Department of Dermatology, P. Poni Research Institute, Romanian Academy Iasi, Romania; 4Department of Dermatology, 5th Military Support Unit, Utska, Poland; 6Department of Histology, 7Department of Dermatology, 8Department of Cardiology; 9Department of Surgery, 10Department of Pathology, University of Medicine and Pharmacy of Targu-Mures, Targu-Mures, Romania

Background: Basal cell carcinoma (BCC) is the most common form of skin cancer, affecting millions of people worldwide. The treatment concept for BCCs is the surgical one, but it is costly, as such, searching for alternative medical therapeutics is justified.

Aim: To highlight the efficacy of high concentration (70%) trichloroacetic acid (TCA) as a choice therapy for low-risk BCC.

Method and patient: Authors present, for the first time, the use of a high concentration TCA applied once a week for 2 consecutive weeks with a toothpick, on a patient with BCC on the right preauricular area.

Results: On examination 4 weeks later, the lesion was not clinically and dermatoscopically evidenced.

Conclusion: High concentration TCA could be an effective and safe, non-invasive choice of therapy for low-risk BCC, easy to perform, not expensive, with good cosmetic results, especially for patients who are not likely to undergo invasive or expensive treatments.

Keywords: basal cell carcinoma, therapy, trichloroacetic acid, dermatology

Introduction

A 38-year-old man, working most of the time indoors as a teacher in a countryside school, far away from a dermatological specialized unit, was seen in consultation during the summer holiday. He described the presence of a crust with minor bleeding while shaving, on the right preauricular area, which had appeared 4 or 5 weeks before. On clinical examination, a small ulcerative (0.75 cm) lesion covered by a crust was noticed, and a presumptive diagnosis of basal cell carcinoma (BCC) was issued. The patient refused any surgical intervention, including biopsy, and he approved of a topical therapy, based on application of 70% trichloroacetic acid (TCA). He was healthy, with no history of either allergy or drug intake, with a low socioeconomic status.

The 70% TCA was applied topically with a toothpick until a white frosting developed and burning sensation was reported by the patient. The burning sensation lasted for less than 10 minutes and the white frosting completely developed on a radius of 0.5 cm around the lesion. A second appointment was made and a new, similar topical TCA treatment was performed 1 week later. The patient described a small crusted ulceration after each application, slight pain, and pruritus. The patient was seen 4 weeks after the last application of topical treatment with no signs of dermatological lesion on the preauricular area (Figure 1). Follow-up at 6-months was recommended, no lesion was observed by clinical and dermatoscopic examination.
BCC is the most common form of skin cancer, affecting millions of people worldwide.1,2 The originating cell belongs to pluripotential cells in the basal layer of the epidermis or follicular structures.

Treatment options for localized BCC include surgery, curettage, laser ablation, cryotherapy, topical application of imiquimod or 5-fluorouracil, photodynamic therapy, and radiotherapy.3

The preference for a treatment modality depends on variable individual factors: tumor location, size, and morphological aspect of the tumor; type of proposed therapy; modality of anesthesia; type of wound closure; risk of complications; time for healing; recurrence rate; cosmetic outcome; costs; job related issues; age and gender; the presence of comorbidities or drug intake; psychiatric illness (cancer phobia); cultural and religious dogmas; and the list could be exhaustive. An important role is played by the physician who deals with a patient diagnosed with BCC and who can persuade the patient to make the most appropriate decision for the present case and moment.

A recent study, using the data retrieved from the Danish Cancer Registry and the Danish Pathology Registry, proved that treatments were performed on a clinical diagnosis in only 21.7% of all BCC cases.4

In daily practice, in superficial small-localized BCC, clinical diagnosis is not backed by a histopathological report, due to the preference of the patients to have a quick, inexpensive, excellent cosmetic outcome in tumors located on the head and neck, with no hospitalization and no close follow-up. They value cure and cosmetic result and reassurance of immediate clinical examination in case of potential recurrence.

TCA is widely used as a peeler in cosmetics for skin rejuvenation, in treating various types of acne, including acne scars, actinic keratosis, epidermal pigmentations, and warts.5 Recent reports have been published regarding the use of TCA in different concentrations in the treatment of xanthelasma palpebrarum.6

The 70% TCA peeling is considered chemocauterization because of its caustic action (epidermal and dermal necrosis), coagulation of epidermal and dermal proteins, necrosis of collagen from upper reticular dermis and protein precipitation.7–9 The 70% TCA applied on the skin produces a “chemical burn” that will be replaced by new epidermal cells. The risk of adverse reactions is low due to the absence of systemic absorption of the TCA.6

The necrotic layers are replaced by “skin seemingly normal” due to re-epithelization from surrounding islets of keratinocytes and from skin appendages in the vicinity of the lesion.

Topical 70% TCA applied once weekly with clinical and dermatoscopic evaluation could be an option for superficial BCC based on significant clinical efficacy, good tolerability, the least number of sessions compared to laser or cryotherapy, low-cost compared to imiquimod, and no need for anesthesia necessary for surgical excision. To the best of our knowledge, this treatment has never been published before in this type of superficial BCC in the literature.

The limitations of the method are the following: lack of histopathological control before and after the therapeutic approach, and the risk of recurrence in the absence of strict surveillance of the patients. Recurrence rate in BCC is high regardless of the treatment; even for the gold standard therapy (surgery) recurrences have been reported in 5.36% of patients after first surgical removal of the tumor, and rising to almost 50% of patients after the third or fourth operation, especially in BCC located in the periocular area.10 Recent reports indicate a recurrence rate of 1.1% per patient diagnosed with BCC after surgical removal by Mohs micrographic surgery.11
Conclusion
The 70% TCA could be an effective and safe non-invasive choice of therapy for low-risk BCCs; easy to perform, inexpensive, with good cosmetic results, especially for patients who are not likely to undergo invasive or expensive treatments.

Contributions
Anca Chiriac made the clinical diagnosis and treated the patient; drafted the article, revised it critically for important intellectual content; and gave final approval of the version to be published. Piotr Brzezinski made substantial contributions to the acquisition of data from the international literature and analysis and interpretation of the data; provided critical revision of the draft for important intellectual content; and gave final approval of the version to be published. Cosmin Moldovan improved the quality of the picture and translated the text; provided critical revision of the draft for important intellectual content; and gave final approval of the version to be published. Cristian Podoleanu made substantial contributions to the acquisition of data from the international literature and analysis and interpretation of the data; provided critical revision of the draft for important intellectual content; and gave final approval of the version to be published. Simona Stolnicu made substantial contributions to the study’s conception and design and to data interpretation; drafted the article and revised it critically for important intellectual content; and gave final approval of the version to be published.

Ethics and consent
The study was approved by the Apollonia University Iasi Ethics Committee.

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Acknowledgement
The authors thank Adrian Naznean from the Department of Foreign Languages of the University of Medicine and Pharmacy of Tîrgu Mureș for careful corrections to the manuscript.

This article was prepared or completed by the authors within their personal capacities. The opinions expressed in this article are the authors’ own and do not reflect the view of the National Institutes of Health.

Disclosure
The authors declare no conflicts of interest in this work.

References